Coloplast sees organic growth
By HME News Staff
Updated 9:17 AM CDT, Wed May 8, 2024
MINNEAPOLIS – Coloplast saw 8% organic growth in its second quarter ended March 31, 2024. Organic growth rates by business area were ostomy care 7%, continence care 8%, advanced wound care 8% and interventional urology 5%. “We deliver a solid second quarter with 8% organic growth and an EBIT margin of 27%, which is in line with our financial guidance,” said Kristian Villumsen, president and CEO, in an interim financial report. “I would like to highlight a strong Q2 performance in our Chronic Care and Advanced Wound Care businesses, as well as solid contributions from our newest members of the Coloplast family, Atos Medical and Kerecis, both of which deliver double-digit growth in Q2. In Continence Care, our new intermittent catheter for men, Luja, is contributing well to growth, and we are now expanding our platform with the launch of Luja for women. In Ostomy Care, we have now received reimbursement in the UK on Heylo, the world’s first digital leakage notification system. We are also strengthening our SenSura Mio portfolio in Ostomy Care with two new launches. I believe these launches will help drive our future growth and make a real difference to people living with intimate chronic conditions worldwide.” Coloplast bought Kerecis in 2023. The company still expects organic revenue growth to be around 8%.
Comments